Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2

Nature Medicine

Volumn 8, Issue 10, 2002, Pages 1098-1104

  Kelly, Gemma ^a   Bell, Andrew ^a   Rickinson, Alan ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE DELETION; GENE EXPRESSION; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE CLONE; PRIORITY JOURNAL; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS LATENCY;

B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL LINE; DOWN-REGULATION; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MYC; VIRAL PROTEINS; VIRUS LATENCY;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0036799565     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm758     Document Type: Article

References (45)

1. Rickinson, A.B. & Kieff, E. in Fields Virology 4th edn., Vol. II (eds. Knipe, D.M. & Howley, P.M.) 2575-2627 (Lippincott, Williams & Raven, Philadelphia, 2001).
2. Rowe, M. et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6, 2743-2751 (1987).
3. Sample, J. et al. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc. Natl. Acod. Sci. USA 88, 6343-6347 (1991).
4. Schaefer, B.C., Woisetschlaeger, M., Strominger, J.L. & Speck, S.H. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc. Natl. Acad. Sci. USA 88, 6550-6554 (1991).
5. Schaefer, B.C., Strominger, J.L. & Speck, S.H. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc. Natl. Acod. Sci. USA 92, 10565-10569 (1995).
6. Nonkwelo, C. et al. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 70, 623-627 (1996).
7. Kieff, E. & Rickinson, A.B. in Fields Virology 4th edn., Vol. II (eds. Knipe, D.M. & Howley, P.M.) 2511-2573 (Lippincott, Williams & Raven, Philadelphia, 2001).
8. Young, L. et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321, 1080-1085 (1989).
9. Woisetschlaeger, M. et al. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc. Natl. Acad. Sci. USA 87, 1725-1729 (1990).
10. Woisetschlaeger, M. et al. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc. Natl. Acad. Sci. USA 88, 3942-3946 (1991).
11. Sung, N.S., Kenney, S., Gutsch, D.E. & Pagano, J.S. EBNA2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J. Virol. 65, 2164-2169 (1991).
12. Abbot, S.D. et al. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J. Virol. 64, 2126-2134 (1990).
13. Fahraeus, R. et al. Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proc. Natl. Acad. Sci. USA 87, 7390-7394 (1990).
14. Wang, F. et al. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64, 3407-3416 (1990).
15. Zimber-Strobl, U. et al. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J. Virol. 65, 415-423 (1991).
16. Kaiser, C. et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73, 4481-4484 (1999).
17. Gregory, C.D. et al. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J. Immunol. 139, 313-318 (1987).
18. Magrath, I. The pathogenesis of Burkitt's lymphoma. Adv. Cancer Res. 55, 133-270 (1990).
19. Babcock, G.J., Hochberg, D. & Thorley-Lawson, D.A. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497-506 (2000).
20. Khanna, R. & Burrows, S.R. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54, 19-4B (2000).
21. Pajic, A. et al. Antagonistic effects of c-Myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int. J. Cancer 93, 810-816 (2001).
22. Finke, J. et al. Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J. Virol. 61, 3870-3878 (1987).
23. Rowe, M. et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25, 1374-1384 (1995).
24. Khanna, R., Burrows, S.R., Argaet, V. & Moss, D.J. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumor cell line. Int. Immunol. 6, 639-645 (1994).
25. Bornkamm, G.W., Hudewentz, J., Freese, U.K. & Zimber, U. Deletion of the nontransforming Epstein-Barr virus strain P3HR-1 causes fusion of the large internal repeat to the DSL region. J. Virol. 43, 952-968 (1982).
26. Rabson, M., Gradoville, L., Heston, L. & Miller, G. Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J. Virol. 44, 834-844 (1982).
27. Hinuma, Y. et al. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J. Virol. 1, 1045-1051 (1967).
28. Jones, M.D., Foster, L., Sheedy, T. & Griffin, B.E. The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J. 3, 813-821 (1984).
29. Parker, B.D. et al. Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology 179, 339-346 (1990).
30. Kempkes, B. et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 14, 88-96 (1995).
31. Yoo, L., Mooney, M., Puglielli, M.T. & Speck, S. B cell lines immortalised with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilisation of the oriP-proximal EBNA gene promoter Wp1. J. Virol. 71, 9134-9142 (1997).
32. Yoo, L. & Speck, S.H. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wildtype viruses recovered from cottontop marmoset lymphoblastoid cell lines. J. Virol. 74, 11115-11120 (2000).
33. Cesarman, E., Dalla-Favera, R., Bentley, D. & Groudine, M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 238, 1272-1275 (1987).
34. Bhatia, K. et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Genet. 5, 56-61 (1993).
35. Goossens, T., Klein, U. & Kuppers, R. Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease. Proc. Natl. Acad. Sci. USA 95, 2463-2468 (1998).
36. Komano, J., Sugiura, M. & Takada, K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J. Virol. 72, 9150-9156 (1998).
37. Ruf, I.K. et al. Epstein-Barr virus regulates c-Myc, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol. Cell. Biol. 19, 1651-1660 (1999).
38. Polack, A. et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl. Acad. Sci. USA 93, 10411-10416 (1996).
39. Gavioli, R. et al. c-Myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nature Cell Biol. 3, 283-288 (2001).
40. Staege, M.S. et al. Myc overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc. Natl. Acad. Sci. USA 99, 4550-4555 (2002).
41. Kovalchuk, A.L. et al. Burkitt lymphoma in the mouse. J. Exp. Med. 192, 1183-1190 (2000).
42. Habeshaw, G. et al. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J. Virol. 73, 965-975 (1999).
43. Rooney, C.M. et al. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J. Natl. Cancer Inst. 77, 681-687 (1986).
44. Tierney, R.J., Steven, N., Young, L.S. & Rickinson, A.B. Epstein-Barr virus latency in blood mononuclear cells-analysis of viral gene-transcription during primary infection and in the carrier state. J. Virol. 68, 7374-7385 (1994).
45. + memory T cells. J. Exp. Med. 186, 859-865 (1997).